Page 190 of 345: studies 1,891 to 1,900 of 3,446, newest first. Back to the MDMA overview
Journal of Clinical Psychopharmacology August 1, 1995 Una D. Mccann, George A. Ricaurte 6 citations
Una D. McCann, MD, NIMH, NIH, Bethesda, Maryland. George A. Ricaurte, MD, PhD, Johns Hopkins Bayview Medical Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Journal of Neuroscience August 1, 1995 Christina Weide Fischer, George Hatzidimitriou, J Wlos et al. 269 citations
The recreational drug (+/)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is a methamphetamine derivative that selectively destroys central 5-HT axons and axon terminals in animals and, possibly, humans. The fate of 5-HT neurons following MDMA injury is uncertain. In particular, while it is known that central 5-HT axons can undergo regenerative sprouting after MDMA injury, it has not been...
British Journal of Pharmacology August 1, 1995 María Isabel Colado, Jodi L. Williams, A.r. Green 165 citations
1. The effect of administration of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') and its N-demethylated product, 3,4-methylenedioxyamphetamine (MDA) on both rectal temperature and long term neurotoxic loss of cerebral 5-hydroxytryptamine (5-HT) has been studied in male and female Dark Agouti (DA) rats. The female metabolizes debrisoquine more slowly than the male and its use has been...
European Journal of Pharmacology July 1, 1995 Norberto Aguirre, J L Galbete, Berta Lasheras et al.
The present study examined the short- and long-term effects of single and repeated administration of 3,4-methylenedioxy-methamphetamine (MDMA, 'ecstasy') on somatodendritic and postsynaptic 5-HT1A receptors of the rat brain. [3H]8-Hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) was used to label 5-HT1A receptors in the brain stem region containing the dorsal raphe nucleus and in the...
Gut June 1, 1995 R S Dykhuizen, P W Brunt, Prescott Atkinson et al. 78 citations
Three cases of jaundice after ingestion of 3,4-methylenedioxymetamphetamine (MDMA), known as 'ecstasy', are reported and the complications associated with the misuse of this drug, which was initially misrepresented as 'safer than alcohol' are described. Ingestion of 'ecstasy' should be considered when investigating unexplained jaundice in younger patients.
Journal of Pharmacology and Experimental Therapeutics June 1, 1995 Bryan K. Yamamoto, J F Nash, Gary A. Gudelsky
The effects of the amphetamine analog, 3,4-methylenedioxymethamphetamine (MDMA) were compared to the effects of d-amphetamine on the in vivo release of dopamine and gamma-aminobutyric acid (GABA) in the striatum and substantia nigra. The brain region-dependent role of the 5-HT2 receptors in the striatum and substantia nigra in regulating MDMA-induced dopamine and GABA release also was studied....
Psychopharmacology June 1995 A R Green, A J Cross, G M Goodwin
3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") was first synthesised 80 years ago, but has recently received prominence as an illegally synthesised recreational drug of abuse. There is a widely held belief among misusers that it is safe. In the last 2-3 years there have been a number of reports of the drug producing severe acute toxicity and death and there are concerns that it may cause...
Brain Research May 1, 1995 S R White, G C Harris, K M Imel et al.
Rats were allowed to self-administer cocaine during a 3-h session for 15 days. One to 11 days after the last cocaine exposure, rats were anesthetized with urethane and effects of microiontophoretically-applied dopamine on glutamate-evoked firing of neurons in the nucleus accumbens and in the caudate/putamen were tested. Dopamine produced a dose-dependent inhibition of glutamate-evoked firing in...
Journal of Pharmacology and Experimental Therapeutics May 1, 1995 J E Sprague, D E Nichols
3,4-Methylenedioxymethamphetamine (MDMA)-induced serotonergic neurotoxicity was assessed in the striatum, hippocampus and frontal cortex of rats by using [3H]paroxetine binding to label serotonin (5-HT) uptake sites and 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels as markers of serotonergic function. NMDA (40 mg/kg) induced a significant decrease in both [3H]paroxetine binding Bmax and...
Brain Research May 1, 1995 Jose C Poblete, Efrain C. Azmitia 52 citations
Neurotransmitters, neuropeptides, and ions regulate glycogen levels in the brain by modulating the activity of glycogen synthase (GSase) and glycogen phosphorylase (GPase). GPase is co-localized with glial fibrillary acidic protein (GFAP), an astroglia-specific marker, suggesting that glycogen is localized in astroglial cells. Additionally, functional serotonin (5-HT) receptors are found in...